Test Compendium is your definitive resource for detailed information on a wide array of diagnostic tests. Each entry in our compendium is meticulously cataloged to aid healthcare providers in selecting and interpreting the right tests for their patients.
Displaying 51 - 75 of 352
D5S23:D5S721/CSF1R Methodology FISH Test Description Probes 5p15.2-p15.31/5q32-q33.1 Disease myelodysplastic neoplasm and AMLThe CSF1R gene is consistently lost by partial deletions occurring in chromosome
CEN8 Methodology FISH Test Description Probes 8p11.1-q11.1 Disease myelodysplastic neoplasm, Myeloproliferative Disorder, Chronic Myelogenous Leukemia, Acute Myeloid Leukemia,Designed to detect copy number
PTPRT/20q11 Methodology FISH Test Description Probes 20q11.21/20q12 Disease MDS, myeloproliferative neoplasm, melanoma and NSCLC.Detection of deletions involving the human PTPRT gene ( Protein tyrosine
ETV6 Methodology FISH Test Description Probes 12p13.2 Disease myelodysplastic neoplasm, Leukemias (AML,ALL, PDGFRB-associated chronic eosinophilic leukemia), congenital fibrosarcomaDetection of abnormalities
MDS FISH Panel Methodology FISH Test Description Probes (5p15.2-p15.31/5q32-q33.1 & 7p11.1-q11.1/7q31.2 & 8p11.1-q11.1 & 20q11.21/20q12 & 12p13.2) Disease myelodysplastic neoplasmcomprehensive
CENX/Y Methodology FISH Test Description Probes Xp11.1-q11.1/Yp11.1-q11.1 Disease MDS, AML and hematologic malignancies.The X/Y chromosome centromere probe .Designed to detect copy number of chromosome
D13S319/13q34(G) Methodology FISH Test Description Probes 13q14.2/13q34 Disease Myeloproliferative Neoplasms, Multiple myeloma, CLLDesign to detect chromosomal abnormalities on chromosome 13 (ch13 deletion/abberations).
MPN FISH Panel Methodology FISH Test Description Probes (8p11.1-q11.1 & 20q11.21/20q12 & 12p13.2 & 13q14.2/13q34 & 9q34.11-q34.13/22q11.22-q11.23) Disease Myelodysplastic neoplasm, Myeloproliferative
IGH/MAF Methodology FISH Test Description Probes 14q32.33/16q23.1-q23.2 Disease Multiple myeloma, MGUSt(14;16) gene fusions involving the IGH gene at 14q32 and the MAF gene at 16q23 is generated during
IGH/MAFB Methodology FISH Test Description Probes 14q32.33/20q12 Disease Multiple Myeloma, MGUSt(14:20) gene fusions involving the IGH gene at 14q32 and the MAFB gene at 20q12 are seen in multiple myeloma
FGFR3/IGH Methodology FISH Test Description Probes 4p16.3/14q32.33 Disease Multiple Myeloma, MGUST(4:14) gene fusions involving the IGH gene at 14q32 and the FGFR3 gene at 4p16 are seen in multiple myeloma
Myeloma Add On Panel Methodology FISH Test Description Probes (14q32.33 & 14q32.33/16q23.1-q23.2 & 14q32.33/20q12 & 4p16.3/14q32.33) Disease Multiple Myeloma, mantle cell lymphoma, Marginal
TP53/CEN17 Methodology FISH Test Description Probes 17p13.1/17p11.1-q11.1 Disease Multiple Myeloma, CLL, AML., ALL, Lymphoma, MDSThe p53 gene is a tumor suppressor gene, which usually controls cell growth
CEN9 Methodology FISH Test Description Probes 9q12 Disease Multiple Myeloma, MPNDesigned to detect copy number variations of the 9q12 region on chromosome 9 and quantitative abnormalities of chromsome
1p36/1q25 Methodology FISH Test Description Probes 1p36.31/1q25.3 Disease Glial tumors, neuroblastoma, multiple myeloma, MPNDetection of deletion of short or long arms of chromsome 1
Myeloma Conventional FISH Panel Methodology FISH Test Description Probes (11q13.3/14q32.33 & 17p13.1/17p11.1-q11.1 & 9q12 & 13q14.2/13q34 & 1p36.31/1q25.3) Disease Multiple Myeloma,Mantle
P. Vera FISH Panel Alternative Name Polycythemia Vera Fish Panel Methodology FISH Test Description Probes (8p11.1-q11.1 & 20q11.21/20q12 & 9q12 & 13q14.2/13q34 & 1p36.31/1q25.3) Disease
MYB/CEN6 Methodology FISH Test Description Probes 6p11.1-q11/6q23.2-23.3 Disease Waldenstrom Macroglobinemia, leukemia, lymphoma, malignant melanomaQualitative detection of amplifications involving the
Waldenstrom FISH Panel Methodology FISH Test Description Probes 6p11.1-q11/6q23.2-23.3 Disease Waldenstrom Macroglobinemia,leukemia, lymphoma, malignant melanomaqualitative detection of amplifications
Her-2/Neu (breast) Alternative Name HER2 Methodology FISH Test Description Probes Her-2/Neu (breast) Disease breast cancer, ovarian cancer, stomach cancer, salivary gland carcinoma, bladder cancer, pancreatic
Her-2/Neu (gastric) Alternative Name HER2 Methodology FISH Test Description Probes Her-2/Neu (gastric) Disease breast, ovarian, bladder, pancreatic, and stomach cancersthatMeasures the amount of HER2/neu
Her-2/Neu IHC (breast) Alternative Name HER2 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes Her-2/Neu IHC (breast) Disease breast, ovarian, bladder, pancreatic, and stomach cancersMeasures
Her-2/Neu IHC (gastric) Alternative Name HER2 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes Her-2/Neu IHC (gastric) Disease breast, ovarian, bladder, pancreatic, and stomach cancersMeasures
Karyotyping Myeloid Methodology Karyotyping Test Description Probes/Genes - Disease subtyping of lymphomas, leukemias and solid tumours for the purpose of exact diagnosis, treatment stratification and
Karyotyping Myeloid - Myeloid (1+2 days) Methodology Karyotyping Test Description Disease Subtyping of lymphomas, leukemias and solid tumours for the purpose of exact diagnosis, treatment stratification
With core values rooted in service and integrity, our leadership team sets the bar high.
We consistently strive to set the model for exactly how a reference laboratory should engage with both physicians and patients.
siParadigm is accredited by CLIA (Clinical Laboratory Improvement Amendments) and certified by CAP (College of American Pathologists).
We also hold select state licensure where required.